NASDAQ$GOCO
GoHealth Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
GoHealth's financial results for Q2 2020 were announced, demonstrating substantial revenue growth and a shift towards technology-driven models.
GoHealth reported a 71% increase in net revenues for the second quarter of 2020, driven by strong Medicare Advantage enrollments. The company's strategic focus on LTV/CAC contributed to industry-leading margins. GoHealth is on track for a record year in fiscal 2020.
- Net revenues for the second quarter of 2020 increased by 71% compared to the prior year period.
- Net loss for the second quarter of 2020 was $(22.9) million, compared to net income of $15.3 million in the prior year period.
- Adjusted EBITDA for the second quarter of 2020 increased by 56% compared to the prior year period.
- The company provided a full year 2020 outlook, including net revenues of $840-890 million.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$127M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
GoHealth provided an outlook for the fiscal year ending December 31, 2020, based on current market conditions and expectations.
Tailwinds
- Full year 2020 net revenue of $840 – $890 million, representing year-over-year growth of 56% – 65%
- Full year 2020 adjusted EBITDA of $265 – $290 million, representing year-over-year growth of 55% – 71%
- COVID-19 pandemic has created favorable industry dynamics for technology-driven direct-to-consumer models
- The company believes it has the winning strategy necessary to deliver great results for its shareholders over the coming years.
- Demand for healthcare has demonstrated great resilience during these times.
Headwinds
- The trajectory of the US economy remains challenging to predict
- There is heightened uncertainty associated with the COVID-19 pandemic.
- The company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans
- The potential for an adverse change in our relationships with carriers, including a loss of a carrier relationships
- Failure to grow the Company’s customer base or retain our existing customers
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-7.7%
Avg return
Earnings day
-9.0%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | — | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro